Quality-adjusted life years assessment using cabozantinib for patients with advanced hepatocellular carcinoma (aHCC) in the CELESTIAL trial.

被引：18
|
作者：
Abou-Alfa, Ghassan K.
Mollon, Patrick
Meyer, Tim
Cheng, Ann-Lii
El-Khoueiry, Anthony B.
Kelley, Robin Kate
Baron, Ari David
Benzaghou, Fawzi
Valcheva, Velichka Valerieva
Hazra, Saswati
Mangeshkar, Milan
Freemantle, Nicholas
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] IPSEN, Abingdon, Oxon, England
[3] UCL, Canc Inst, London, England
[4] Natl Taiwan Univ Hosp, Taipei, Taiwan
[5] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan
[6] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[7] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[8] Pacific Hem Onc Assoc, Mill Valley, CA USA
[9] IPSEN, Paris, France
[10] Ipsen Pharma SAS, Paris, France
[11] Prometheus Lab Inc, San Diego, CA USA
[12] Exelixis Inc, San Francisco, CA USA
[13] UCL, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期
关键词：
D O I：
10.1200/JCO.2019.37.4_suppl.207
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
207
引用
收藏
页数：2
相关论文
共 50 条
  • [21] The quality-adjusted life-years in the oncological patients' health-related quality of life
    Kucnerowicz, Karolina
    Pietrzak, Agata
    Cholewinski, Witold
    Martenka, Piotr
    Marszalek, Andrzej
    Burchardt, Ewa
    Strzesak, Erwin
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [22] The quality-adjusted life-years in the oncological patients’ health-related quality of life
    Karolina Kucnerowicz
    Agata Pietrzak
    Witold Cholewiński
    Piotr Martenka
    Andrzej Marszałek
    Ewa Burchardt
    Erwin Strzesak
    Scientific Reports, 12
  • [23] Quality of life and quality-adjusted life years of chronic schistosomiasis mansoni patients in Brazil in 2015
    Nascimento, Gilmore Lima
    Coutinho Domingues, Ana Lucia
    de Alencar Ximenes, Ricardo Arraes
    Itria, Alexander
    Cruz, Luciane Nascimento
    Fernandes de Oliveira, Maria Regina
    TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2018, 112 (05) : 238 - 244
  • [24] Re: Quality-Adjusted Survival with First-Line Cabozantinib or Sunitinib for Advanced Renal Cell Carcinoma in the CABOSUN Randomized Clinical Trial (Alliance)
    Laguna, Pilar M.
    JOURNAL OF UROLOGY, 2021, 205 (06): : 1819 - 1820
  • [25] ESTIMATING LIFE YEARS AND QUALITY-ADJUSTED LIFE YEARS IN HEAVILY TREATMENT-EXPERIENCED (HTE) PATIENTS
    McEwan, P.
    Darlington, O.
    van Doornewaard, A.
    Webster, S.
    Ward, T.
    Martin, A. A.
    Punekar, Y. S.
    VALUE IN HEALTH, 2017, 20 (09) : A790 - A790
  • [26] Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma
    Rimassa, Lorenza
    Kelley, Robin Kate
    Meyer, Tim
    Ryoo, Baek-Yeol
    Merle, Philippe
    Park, Joong-Won
    Blanc, Jean-Frederic
    Lim, Ho Yeong
    Tran, Albert
    Chan, Yi-Wah
    McAdam, Paul
    Wang, Evelyn
    Cheng, Ann-Lii
    El-Khoueiry, Anthony B.
    Abou-Alfa, Ghassan K.
    LIVER CANCER, 2021, : 38 - 47
  • [27] Outcomes based on plasma biomarkers for the Phase III CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma
    Zekry, A.
    Rimassa, L.
    Kelley, R.
    Meyer, T.
    Ryoo, B.
    Merle, P.
    Park, J.
    Blanc, J.
    Lim, H.
    Tran, A.
    Borgman-Hagey, A.
    Clary, D.
    Wang, E.
    Cheng, A.
    El-Khoueiry, A.
    Abou-Alfa, G.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 41 - 42
  • [28] QUALITY OF LIFE (QOL) IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (AHCC) IN CLINICAL TRIALS AND HEALTH TECHNOLOGY APPRAISAL (HTA) IMPLICATIONS
    Moon, J.
    Hurtado, P.
    Lucchino, M.
    Sathi, C.
    Vidalis, A.
    Demont, E.
    Gulotta, G.
    Dumoulin, O.
    VALUE IN HEALTH, 2022, 25 (07) : S572 - S572
  • [29] Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced Hepatocellular Carcinoma (HCC)
    Waidmann, O.
    Merle, P.
    Rimassa, L.
    Ryoo, B-Y
    Cicin, I
    Harris, W. P.
    Nemunaitis, J.
    Olteanu, S.
    Sarker, D.
    Tan, B. R.
    Van Vlierberghe, H.
    Sen, S.
    Love, C.
    Cheng, A-L
    El-Khoueiry, A. B.
    Meyer, T.
    Kelley, R. K.
    Abou-Alfa, G. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 283 - 284
  • [30] Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma (HCC)
    Merle, P.
    Rimassa, L.
    Ryoo, B.
    Cicin, I.
    Harris, W.
    Banu, E.
    Sarker, D.
    Tan, B.
    Van Vlierberghe, H.
    Sen, S.
    Love, C.
    Cheng, A.
    Meyer, T.
    Kelley, R.
    Abou-Alfa, G.
    ANNALS OF ONCOLOGY, 2018, 29 : 104 - 104
12345